EMA publishes EPAR for Qtern (saxagliptin hydrochloride with dapagliflozin propanediol monohydrate)

27 July 2016 - The EMA has published an EPAR for AstraZeneca's Qtern.

The European Commission approved Qtern on 15 July 2016 for the use by adults aged 18 years and older with type 2 diabetes mellitus:

  • to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,
  • when already being treated with the free combination of dapagliflozin and saxagliptin

Read EPAR for Qtern

Michael Wonder

Posted by:

Michael Wonder